Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rilotumumab + ECX in advanced MET-positive gastric cancer
NCT01697072Phase 3Terminated
- Sponsor
- Amgen
- Start
- Oct 2012
- Primary completion
- Nov 2014
- Modality
- Antibody Conjugates, Recombinant Proteins and Enzymes, Engineered Antibody Formats
- Countries
- 27
01
Overview
Phase 3, randomised, double-blind trial in gastric cancer (GC) and gastroesophageal junction adenocarcinoma comparing Rilotumumab + ECX with Placebo + ECX (2 arms). Primary endpoint: Overall Survival at 3 years. Started Oct 2012; status: terminated.
02
Drugs
rilotumumab
03
Conditions
gastric cancer (GC)gastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT01697072.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01697072.